Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-07

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH

NCT04627701

Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms

RECRUITING NA

Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years

NCT02757963

Prostatic Hyperplasia

COMPLETED PHASE4

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919

Benign Prostatic Hyperplasia

COMPLETED NA

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

NCT04987892

BPH

RECRUITING PHASE4

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030

Benign Prostatic Hyperplasia

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omega procedure

Group Type EXPERIMENTAL

Omega device

Intervention Type DEVICE

The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.

The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega device

The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.

The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male ≥50 years of age and ≤ 80 years old.
2. Will undergo planned prostatectomy.
3. Participant understands and is willing to the informed consent form.
4. Prostate Volume between 30cc and 80cc.
5. Prostate length ≥ 3cm

1. Male ≥50 years old.
2. Suspected symptomatic benign prostatic hyperplasia (BPH).
3. International Prostate Symptom Score (IPSS) \>13.
4. Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
5. Participant understands and is willing to the informed consent form.
6. Prostate Volume between 30cc and 80cc.
7. Prostate length ≥ 3cm and ≤ 5cm

Exclusion Criteria

1. Unable to comply with the clinical protocol.
2. Vulnerable population such as inmates or developmentally delayed individuals.
3. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:

* Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy is not prohibited).
* Use of alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
* Use of 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.
4. American Society of Anesthesiologists score (ASA) \> 3.
5. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
6. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
7. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
8. Previous rectal surgery, other than hemorrhoidectomy
9. Current gross hematuria.
10. Known allergy to nickel or titanium or stainless steel.

Stage 2

1. Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.
2. Concomitant participation in another interventional study.
3. Unable to comply with the clinical protocol including all the follow-up requirements.
4. Vulnerable population such as inmates or developmentally delayed individuals.
5. Significant comorbidities which would affect study participation.
6. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure ,such as:

* Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
* Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
* Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
* Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).
* Patient is taking steroids. \[Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers.\]
7. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
8. Compromised renal function due to obstructive uropathy.
9. Active Urinary Tract Infection (UTI).
10. Obstructive or protruding median lobe.
11. American Society of Anesthesiologists score (ASA) \> 3.
12. Known neurogenic bladder or neurological disorders that might affect bladder or function.
13. Recent myocardial infarction (less than three months).
14. Concomitant bladder stones.
15. Current gross hematuria.
16. Active or history of epididymitis within the past 3 months.
17. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
18. Confirmed or suspected malignancy of bladder.
19. History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.
20. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
21. Bacterial prostatitis within the last 12 months.
22. Previous rectal surgery, other than hemorrhoidectomy.
23. Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).
24. Known allergy to nickel or titanium or stainless steel.

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No